#503 AceTwinTower1cha Gurodigital complex, Gurodong, Seoul. 08381
Tel: +82 2 861 0316
What we do
Naturally occurring viruses are live replication-proficient viruses specifically infecting human cancer cells while sparing their normal counterparts.
Since the discovery of naturally oncotropic viruses in the 1920s, various replicating viruses have shown degrees of safety and efficacy in pre-clinical and clinical application for human anti-cancer therapeutics. Cellular oncogenes such as Ras and c-Myc are known to be important host genes for oncolytic viral tropism decision.
Importantly, we recently discovered that cellular tumor suppressor genes are also important in determining oncolytic viral tropism. Carcinogenesis is a multi-step process involving accumulation of not only oncogene abnormality but also the accumulation of tumor suppressor gene abnormality. Thus, it is interesting that oncolytic viruses are known to exploit abnormal oncogene and cellular tumor suppressor signaling, frequently dysregulated in various human malignancies, for their decision of oncolytic specificity and efficacy.
Unlike oncogenes, many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity & maintenance. Thus tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects resulting in natural viral oncotropism.
ViroCure finds naturally occurring oncotropic viruses for targeting various human or animal malignancies, to develop safe and effective treatments to a wide variety of illnesses.
Highlights
Feb 2023
RC402-IT Australia Phase 1 clinical trial (1a/1b) completed successfully.
June 2022
Cancer surgeon Prof. Dong-guk Park appointed CEO
Feb 2022
Established CuroV Science, Inc. in Ottawa, Canada
2021
RC402-IT Australia Phase 1 clinical trial (1a/1b) in progress
July 2020
Strategic R&D co-op. agreement with CHA Bundang Medical Center & strategic partnership with Y Biologics
October 2019
Established ViroCure Australia in Brisbane
April 2019
Investment & strategic partnership with EDGC
December 2017
Strategic co-op. agreement with Seoul Asan Hospital
September 2017
Opened ViroCure USA lab at Moffit Cancer Center
June 2016
Established ViroCure, Inc.
2013
Established Cancer Virus Research Center at Dankook University College of Medicine for OV research
1999
Foundational research on oncolytic virology at the University of Calgary
Leadership Team
Dr. Wangjun Lee, CEO
Chairman, Myongji Medical Foundation
CEO, MJCELLBIO Co, Ltd.
President, Asian Oncolytic Virus Association
CEO, DxVx (formerly CancerRop)
Seoul National Univ. Med School MD, Ph.D
Prof. Dong Guk Park, CTO & Chairman of the Board
Dankook Univ. Med School, Director of Cancer Center, Chief Surgeon, Dean of Graduate Medical School
Univ. of Calgary, Visiting Professor
Seoul National Univ. Med School MD, Ph.D
Prof. Nam Hyuk Cho, CSO
Professor, SNU Medical School
Harvard Medical School, Post-doc
SNU Medical School, PhD
Prof. Tommy Alain, CSO North America
CEO, CuroV Science, Inc.
University of Ottawa
CHEO Research Institute
Microbiology & Immunology
Haeng Jun Yoo, Executive Advisor
CEO, Amicogen, Inc.
President, Jeonbuk Institute for Bioindustry
CEO, CJ Cheiljedang Bio Business Unit
Samsung Group Chairman's Office
Seoul National University
Scientific Advisory Board
Prof. Chungsoo Kim
ASAN Medical Center
Prostrate Cancer
Prof. Minhee Ryu
ASAN Medical Center
Medical Oncology
Prof. Woochan Son
ASAN Medical Center
Pathology
Veterinary Science
Prof. Hongjae Jeon
Bundang CHA Hospital
Director, Cancer Center
Prof. Chan Kim
Bundang CHA Hospital
Colorectal, Urinary, Sarcoma